Organization | Austrian Science Fund (FWF)

Austrian Science Fund (FWF) Report issue

Government Phase 2 Phase 3 Phase 4

Founded: Vienna Germany (1968)

Organization Overview

First Clinical Trial

2002

NCT00704314

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Now

Alternative names

Austrian Science Fund (FWF)

Active Ingredients

Drugs in Phase 4 Trials (1)

vitamin d3 (2 trials)

Drugs in Phase 3 Trials (2)

imiquimod (aldara) (1 trial)

miglitol (glyset) (1 trial)

Drugs in Phase 2 Trials (3)

birch allergen (1 trial)

rbet v1-fv (1 trial)

tick-borne encephalitis vaccine (TICOVAC) (1 trial)

Drugs in Other Trials (4)

lactobacillus plantarum (1 trial)

lactobacillus rhamnosus (1 trial)

lactobacillus salivarius (1 trial)

simvastatin (zocor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma in Situ (Phase 3)

Dermatitis, Contact (Phase 3)

Encephalitis (Phase 2)

Encephalitis, Tick-Borne (Phase 2)

Exanthema (Phase 3)

Hypersensitivity (Phase 2)

Neoplasms (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 2)

Vitamin D Deficiency (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 10